Johnson & JohnsonvsMineralys Therapeutics

JNJ and MLYS stock compared: price, dividend, valuation and results, from SEC filings.

MLYS

Mineralys Therapeutics, Inc.

$13.66

Value $1.2B

-3.53%
MLYS's page

Johnson & Johnson (JNJ) has a market value of $652B and Mineralys Therapeutics (MLYS) $1.2B. Over the last year, with dividends, JNJ moved +36.6% and MLYS -67.6%. Dividend yield: JNJ 1.95%, MLYS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    MLYS$1.2B

    JNJ is 539 times MLYS

  • Revenue, 12 months

    JNJ$99.3B

    MLYS–

  • Net income, 12 months

    JNJ$16.1B

    MLYS-$370M

  • Operating margin

    JNJ–

    MLYS–

  • ROIC

    JNJ12.4%

    MLYS-20.8%

    33.2 points apart

  • P/E

    JNJ40.5

    MLYS–

  • Dividend yield

    JNJ2.0%

    MLYS0.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+94.9%

MLYS+112.4%

200400600202420252026
Returns by period
PeriodJNJWith dividendsMLYSWith dividends
1 year since November 19, 2025+36.6%Price +33.6%-67.6%Price -67.6%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%+112.4%+28.6% a yearPrice +112.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonMLYSMineralys Therapeutics

Valuation

JNJMLYS
Valuation
Price$270.47$13.66
Market value$652B$1.2B
Enterprise value (EV)$679B$585M
P/E40.5–
P/E, 5-year median21.9–
P/B8.02.4
EV/EBIT38.3–
Free cash flow yield3.2%–

Results and growth

JNJMLYS
Results and growth
Revenue, 12 months$99.3B–
Net income, 12 months$16.1B-$370M
Free cash flow, 12 months$20.6B-$153M
Earnings per share, 12 months$6.59-$4.31
Revenue growth, year on year6.1%–
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJMLYS
Margins and returns on capital
Gross margin67.6%–
Operating margin––
Net margin16.2%–
ROIC12.4%-20.8%
ROE19.7%-63.4%

Balance sheet

JNJMLYS
Balance sheet
Cash$17.2B$625M
Total debt$44.7B$100.0K
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJMLYS
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or MLYS

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Mineralys Therapeutics?

By market value, Johnson & Johnson ($652B) is about 538.8 times Mineralys Therapeutics ($1.2B), at today's prices.

How did JNJ and MLYS stock do over the last 3 years?

Since November 20, 2023, JNJ's price moved +80.4% and MLYS's +112.4%. With dividends: JNJ +94.9% (+24.9% a year), MLYS +112.4% (+28.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or MLYS?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Mineralys Therapeutics. Over the last twelve months they paid $5.28 and – per share.

Which is the better investment, Johnson & Johnson or Mineralys Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.